Demonstrated improvement in nasal congestion/obstruction vs. placebo 52 weeks

DUPIXENT® significantly improved NC score from baseline vs. placebo + INCS at week 24 and week 521,3

Line graph showing the LS mean change from baseline in nasal congestion score in SINUS-52 over time. The x-axis ranges from weeks 0 through 52. 153 subjects are in the placebo treatment arm and 150 are in the DUPIXENT arm. At Week 52, the mean change in nasal congestion score in the DUPIXENT group was -1.35 (from a baseline score of 2.48) versus -0.37 (from a baseline score of 2.38) in the placebo group. These results amount to a 54% improvement in nasal score for the DUPIXENT group and a 16% improvement for the placebo group.
Adapted from Bachert C, et al.

> 51% improvement at week 24 (co-primary endpoint) with DUPIXENT® (n=295, pooled DUPIXENT® arms) (-1.25 from baseline score 2.46) vs. 16% improvement with placebo (n=153) (-0.38 from baseline score 2.38) (LSM difference: -0.87 [95% CI -1.03, -0.71])

Nasal congestion/obstruction (NC) score was rated daily by patients on a 0-3 categorical severity scale (0=no symptoms; 1=mild symptoms; 2=moderate symptoms; 3=severe symptoms).
Reduced score indicates improvement.
LSM: least squares mean.

Connect With a Rep

Have questions about DUPIXENT®? Get answers from a representative.

Freedom support program logo.

Freedom Support Program

Find out what the Freedom Support Program can bring to your patients and how you can help them access it.



DUPIXENT®, Sanofi and Freedom logos are trademarks of Sanofi, used under license by sanofi-aventis Canada Inc.
REGENERON® is a trademark of Regeneron Pharmaceuticals, Inc. All rights reserved.
© 2023 sanofi-aventis Canada Inc. All rights reserved.

MAT-CA-2300229E
Last updated: 06/2023

paab logo